BerandaBMRN • NASDAQ
add
Biomarin Pharmaceutical Inc
Tutup sebelumnya
$59,32
Rentang hari
$58,74 - $61,26
Rentang tahun
$52,93 - $94,85
Kapitalisasi pasar
11,55Â M USD
Volume Rata-Rata
1,87Â jt
Rasio P/E
22,35
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 745,14Â jt | 14,84% |
Biaya operasional | 210,96Â jt | -12,17% |
Laba bersih | 185,69Â jt | 109,43% |
Margin laba bersih | 24,92 | 82,43% |
Penghasilan per saham | 1,13 | 59,15% |
EBITDA | 245,96Â jt | 132,45% |
Tarif pajak efektif | 22,01% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,27Â M | 21,57% |
Total aset | 7,15Â M | 3,99% |
Total liabilitas | 1,35Â M | -24,76% |
Total ekuitas | 5,79 M | — |
Saham yang beredar | 191,78 jt | — |
Harga terhadap nilai buku | 1,96 | — |
Tingkat pengembalian aset | 7,92% | — |
Tingkat pengembalian modal | 8,82% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 185,69Â jt | 109,43% |
Kas dari operasi | 174,39Â jt | 271,28% |
Kas dari investasi | -28,24Â jt | -98,36% |
Kas dari pembiayaan | -38,78Â jt | 9,38% |
Perubahan kas bersih | 105,96Â jt | 1.403,17% |
Arus kas bebas | 102,79Â jt | 376,04% |
Tentang
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Didirikan
Mar 1997
Kantor pusat
Situs
Karyawan
3.040
